Winship Cancer Institute of Emory University | Strategic Alliance Partners

October 13, 2022

Kevin Kalinsky, MD, MS, discusses the role of chemotherapy with ovarian function suppression and hormonal therapy for premenopausal patients with HR–positive/HER2-negative breast cancer.

October 07, 2022

Jonathon B. Cohen, MD, MS, discusses the adverse effects associated with BTK inhibitors in chronic lymphocytic leukemia.

October 07, 2022

Jane Lowe Meisel, MD, discussed the emergence of HER2-low as a new category in breast cancer, outlining the significance of the phase 3 DESTINY-Breast04 trial and the unique qualities of trastuzumab deruxtecan in the HER2-positive and HER2-low populations.

October 06, 2022

Nabil Saba, MD, FACP, discusses the disparities seen in clinical trials in head and neck cancer.

October 05, 2022

Jonathon B. Cohen, MD, MS, discusses the evolution of treating patients with additional comorbidities in chronic lymphocytic leukemia.

October 05, 2022

Suchita Pakkala, MD, discusses the importance for clinical trial enrollment for patients with breast cancer who have brain metastases.

September 26, 2022

Victor M. Orellana-Noia, MD, discusses the treatment of high-risk and vulnerable patients with diffuse large B-cell lymphoma.

September 23, 2022

Victor M. Orellana-Noia, MD, discusses the patient population of the phase 3 POLARIX trial in diffuse large B-cell lymphoma.

August 17, 2022

Maintenance rituximab following first-line bendamustine plus rituximab or a combination of rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone prolonged first-line treatment benefits and improved survival outcomes vs either induction regimen alone.

August 08, 2022

EGFR C797X mutations have become a leading mechanism of acquired resistance following treatment with the third-generation EGFR inhibitor osimertinib, outpacing MET amplification.

July 15, 2022

Premenopausal patients with early hormone receptor–positive, HER2-negative breast cancer can benefit from chemotherapy, although it is still debatable whether that benefit stems from the chemotherapy itself or the ovarian function suppression that happens as a result of chemotherapy.

June 14, 2022

Mehmet A. Bilen, MD, and a panel of renal cell carcinoma experts discuss the preferred treatment options for patients with intermediate-risk or high-risk advanced renal cell carcinoma and the clinical features that may influence their decisions.

June 07, 2022

OncLive® will be LIVE with OncLive® News Network: On Location at the 2022 ASCO Annual Meeting. Each day, we will broadcast a series of interviews with top thought leaders, to learn their thoughts and reactions to data presented across oncology during the conference.

June 05, 2022

Ribociclib plus endorcrine therapy led to a statistically significant improvement in progression-free survival in patients with hormone receptor–positive, HER2-negative unresectable or metastatic breast cancer with tumor progression following treatment with a CDK4/6 inhibitor, according to findings from the randomized phase 2 MAINTAIN trial.

May 04, 2022

Kevin Kalinsky, MD, MS, discusses updates from the phase 3 TAILORx trial in patients with hormone receptor–positive or HER2-negative breast cancer with node-negative disease.

April 26, 2022

Kevin Kalinsky, MD, MS, discusses the potential benefits of chemotherapy in preventing disease recurrence in premenopausal patients with breast cancer.

March 30, 2022

Suresh S. Ramalingam, MD, FACP, FASCO, discusses the exploration of patritumab deruxtecan in non–small cell lung cancer.

March 30, 2022

Suresh S. Ramalingam, MD, FACP, FASCO, discusses ongoing trials investigating osimertinib combination approaches in non-small cell lung cancer.

March 29, 2022

Suresh S. Ramalingam, MD, FACP, FASCO, discusses current applications for frontline immunotherapy and targeted therapy for non–small cell lung cancer and the current management of small cell lung cancer.

March 10, 2022

Since most diagnoses of esophageal squamous cell carcinoma are made when the disease is in advanced stages, investigators have initiated studies to evaluate the efficacy of immunotherapy in earlier lines of therapy, including in combination with chemoradiotherapy.